| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | E.coli-derived human PLAGL2 recombinant protein (Position: K269-E365) was used as the immunogen for the PLAGL2 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
PLAGL2 Antibody / Pleiomorphic adenoma gene-like 2 is a anti-PLAGL2 Rabbit antibody Polyclonal (rabbit origin) supplied in Lyophilized format. Recommended for workflows such as Western blot (WB), ELISA with listed reactivity in Human, Mouse, Rat.
Key elements and design rationale
- Target: PLAGL2
- Antibody details: Rabbit, Polyclonal (rabbit origin), isotype Rabbit IgG
- Format: Lyophilized
- Applications (as listed): WB, ELISA
Biological background
Structurally, PLAGL2 contains seven C2H2-type zinc finger domains that enable DNA binding and transcriptional activation of target genes such as IGF2, PAI-1, and NRP1. It interacts with coactivators and chromatin remodeling proteins to modulate gene transcription linked to growth and migration. PLAGL2 contributes to the regulation of Wnt and hypoxia signaling pathways by activating genes involved in angiogenesis and metabolic adaptation.
The PLAGL2 antibody is widely used in cancer biology, developmental biology, and transcriptional regulation research to study gene activation and oncogenic signaling. Western blot analysis typically identifies a 57 kilodalton band corresponding to PLAGL2, while immunofluorescence shows nuclear localization consistent with its role as a transcriptional regulator. This antibody allows investigation of transcriptional networks and regulatory mechanisms controlling cellular transformation and differentiation.
In oncology, PLAGL2 has been implicated in colorectal, lung, and brain cancers where it promotes stem-like characteristics, epithelial-mesenchymal transition, and resistance to apoptosis. Conversely, in certain developmental contexts, PLAGL2 supports normal differentiation by activating lineage-specific genes. The PLAGL2 antibody provides a powerful tool for exploring these complex regulatory roles in tumor and stem cell biology.
Research relevance and current trends
- Connecting protein-level changes to phenotype using orthogonal readouts (genetic perturbation, transcriptomics, imaging).
- Considering isoforms and post-translational regulation when interpreting protein-level changes.
- Comparing results across species and model systems with matched controls.
Common research applications
- Western blotting: compare relative abundance and activation-state changes across conditions.
- ELISA: support antibody-based quantification in assay formats where applicable.
Interpret changes in signal alongside appropriate controls and, when relevant, in parallel with total-protein or pathway readouts.
Notes for experimental interpretation
- Signal can reflect expression level, isoform composition, and post-translational state; interpret results in the context of your model system and stimuli.
- Species differences and sample matrices can influence epitope recognition; prioritize matched controls and orthogonal confirmation when feasible.
Antibody notes: Polyclonal antibodies recognize multiple epitopes, which can broaden the epitope footprint and may increase sensitivity in some contexts.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
